Bristol-Myers Squibb signs research agreement

Published: 8-Jul-2005

Codexis, a privately held bioscience company applying proprietary protein and strain engineering technologies to create process development solutions for environmentally friendly pharmaceutical manufacturing, has signed a pharmaceutical process research agreement with Bristol-Myers Squibb (BMS).


Codexis, a privately held bioscience company applying proprietary protein and strain engineering technologies to create process development solutions for environmentally friendly pharmaceutical manufacturing, has signed a pharmaceutical process research agreement with Bristol-Myers Squibb (BMS).

In addition to its relationship with BMS, Codexis has 10 strategic alliances in life science and chemistry process development, where its technology is being applied to reduce process development time and manufacturing costs while creating new intellectual property opportunities.

The research with BMS focuses on improving biocatalyst productivity for an undisclosed product candidate in BMS' pipeline, using Codexis' proprietary pharmaceutical process re-engineering platform. Codexis will receive research funding and a milestone payment upon successful completion of certain objects of the research. If BMS is satisfied with the progress of the research, the agreement may subsequently be expanded to fund additional research. Financial terms were not disclosed.

You may also like